Puma Biotechnology (PBYI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual Meeting of Stockholders scheduled for June 11, 2025, at the company's Los Angeles office.
Proxy materials, including the annual report and proxy statement, are available online for review and voting.
Shareholders of record as of April 21, 2025, are eligible to vote at the meeting.
Voting matters and shareholder proposals
Election of eight director nominees for a one-year term is on the agenda.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2025.
Advisory (non-binding) vote to approve executive compensation as described in the proxy statement.
Board recommends voting "FOR" all proposals.
Board of directors and corporate governance
Eight director nominees listed for election, including Alan H. Auerbach, Alessandra Cesano, Allison Dorval, Michael P. Miller, Jay M. Moyes, Adrian M. Senderowicz, Brian Stuglik, and Troy E. Wilson.
Latest events from Puma Biotechnology
- Q4 2025 delivered strong revenue and profit growth, with NERLYNX sales and clinical progress driving outlook.PBYI
Q4 202528 Mar 2026 - NERLYNX sales rise, alisertib progresses in trials, and profitability is maintained.PBYI
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Q2 2024 revenue rose sequentially, net loss narrowed, and FY net income is projected at $12M–$15M.PBYI
Q2 20242 Feb 2026 - Q3 2024 net income surged to $20.3M on $80.5M revenue, with strong China sales and global growth.PBYI
Q3 202415 Jan 2026 - Q4 2024 saw stable NERLYNX sales, higher net income, and a steady 2025 outlook.PBYI
Q4 202426 Dec 2025 - NERLYNX and alisertib advance with stable revenue and key clinical data expected in 2025.PBYI
TD Cowen 45th Annual Healthcare Conference17 Dec 2025 - Board recommends voting for all directors, auditor ratification, and executive pay approval.PBYI
Proxy Filing2 Dec 2025 - Q1 2025 net income reached $3.0M on $46.0M revenue, with FY 2025 guidance raised.PBYI
Q1 202526 Nov 2025 - Q2 2025 returned to profitability with strong NERLYNX sales and improved margins.PBYI
Q2 202523 Nov 2025